Peptide · Fact sheet
Lixisenatide
Also known as Adlyxin · Lyxumia · lixisenatide acetate
Lixisenatide is not FDA approved for Parkinson disease or neuroprotection. Its former U.S. Adlyxin products were approved for type 2 diabetes and are listed by FDA as discontinued; a small Phase 2 Parkinson trial needs larger confirmation.
What is Lixisenatide?
Lixisenatide is a peptide GLP-1 receptor agonist developed for glucose control in type 2 diabetes.
Interest in Parkinson disease comes from possible brain and inflammatory effects of GLP-1 signaling, not from the former diabetes approval.
Benefits people look for
The LIXIPARK trial reported less worsening on a motor score than placebo after one year.
That signal contrasts with a negative Phase 3 exenatide trial and makes replication, molecule differences, and study design especially important.
What the evidence supports
- LIXIPARK found less average worsening on the primary motor score than placebo over the controlled period.
- The study was not large enough to establish routine treatment, long-term disease modification, or broad class efficacy.
All research areas
- Type 2 diabetes
- Early Parkinson disease
- Motor disability progression
- GLP-1 neurobiology
- Parkinson disease progression and neuroprotection
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- Nausea and vomiting were frequent in the Parkinson trial and affected tolerability.
- The former diabetes label described pancreatitis, severe gastrointestinal reactions, kidney injury, hypoglycemia in some combinations, and hypersensitivity risks.
- A discontinued commercial product and an investigational neurologic use create distinct access and evidence questions.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Moderate human evidenceDiabetes efficacy was sufficient for the former approval. Parkinson evidence is limited to a relatively small Phase 2 trial with a motor-score signal, substantial gastrointestinal adverse effects, and no proof of disease modification.
Selected research to read
Controlled early-Parkinson study reporting a motor-score signal and gastrointestinal adverse effects.
FDA approval & research status
FDA records list the U.S. Adlyxin presentations as discontinued. The prior approval covered glycemic control in adults with type 2 diabetes, not Parkinson disease.
No FDA-approved use is documented in the records summarized on this page.
U.S. product discontinued
Lixisenatide had an FDA-approved diabetes product, but the cited FDA product record and label context support treating the U.S. product as discontinued rather than currently marketed.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Whether a larger confirmatory Parkinson trial will reproduce the motor signal
- Whether the effect is symptomatic or disease modifying
- Longer-term neurologic outcomes and tolerability
- Why lixisenatide and exenatide trials produced different results
The takeaway
Lixisenatide offers a real Parkinson research signal, but not an approved neurologic treatment. The discontinued U.S. product, small trial, and tolerability burden all matter.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA Purple Book: Adlyxin product status
FDA record showing approval details and discontinued marketing status.
- 2fdaFDA prescribing information: Adlyxin
Former diabetes indication, warnings, adverse reactions, and clinical evidence.
- 3pubmedLIXIPARK randomized Phase 2 trial
Controlled early-Parkinson study reporting a motor-score signal and gastrointestinal adverse effects.